See more : Tassal Group Limited (TSLLF) Income Statement Analysis – Financial Results
Complete financial analysis of TRxADE HEALTH, Inc. (MEDS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of TRxADE HEALTH, Inc., a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
You may be interested
- Granite Ridge Resources, Inc (GRNT) Income Statement Analysis – Financial Results
- Donegal Group Inc. (DGICA) Income Statement Analysis – Financial Results
- Lam Research Corporation (LRCX.BA) Income Statement Analysis – Financial Results
- Shanghai W-Ibeda High Tech.Group Co.,Ltd. (688071.SS) Income Statement Analysis – Financial Results
- Panacea Biotec Limited (PANACEABIO.NS) Income Statement Analysis – Financial Results
TRxADE HEALTH, Inc. (MEDS)
About TRxADE HEALTH, Inc.
TRxADE HEALTH, Inc. operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement. It operates the TRxADE drug procurement marketplace, which fosters price transparency and serves approximately 11,800 members; and offers patient centric telehealth services under the Bonum Health brand name. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. is based in Land O' Lakes, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.27M | 11.45M | 9.89M | 17.12M | 7.44M | 3.83M | 2.93M | 2.48M | 4.99M | 1.50M | 955.88K | 806.05K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 5.67M | 6.00M | 5.14M | 11.42M | 2.57M | 449.05K | 0.00 | 16.36K | 1.93M | 440.05K | 944.07K | 689.81K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.60M | 5.45M | 4.75M | 5.71M | 4.87M | 3.38M | 2.93M | 2.47M | 3.06M | 1.06M | 11.81K | 116.24K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 31.41% | 47.62% | 47.99% | 33.33% | 65.50% | 88.28% | 100.00% | 99.34% | 61.38% | 70.59% | 1.24% | 14.42% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.38M | 1.16M | 1.37M | 662.73K | 647.14K | 949.95K | 375.17K | 286.76K | 319.44K | 319.44K | 611.71K | 198.41K | 0.00 | 0.00 | 3.57K |
| General & Administrative | 8.48M | 7.05M | 8.81M | 7.49M | 4.38M | 2.35M | 2.27M | 3.30M | 3.70M | 2.11M | 2.10M | 266.95K | 28.50M | 0.00 | 5.16K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 147.63K | 355.12K | 374.62K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.48M | 7.05M | 8.81M | 7.49M | 4.38M | 2.35M | 2.27M | 3.45M | 4.05M | 2.49M | 2.10M | 266.95K | 28.50M | 24.77K | 5.16K |
| Other Expenses | 14.54K | 1.60M | -1.23M | 3.25M | 72.08K | 161.64K | 67.50K | 131.27K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.42K | 0.00 |
| Operating Expenses | 9.86M | 8.21M | 8.81M | 7.49M | 4.38M | 3.30M | 2.27M | 3.45M | 4.05M | 2.49M | 2.10M | 266.95K | 28.50M | 28.19K | 8.73K |
| Cost & Expenses | 15.54M | 14.20M | 13.96M | 18.90M | 6.94M | 3.75M | 2.27M | 3.47M | 5.98M | 2.93M | 3.04M | 956.76K | 28.50M | 28.19K | 8.73K |
| Interest Income | 4.20K | 20.99K | 23.59K | 29.39K | 53.23K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.20M | 336.21K | 23.59K | 29.39K | 53.23K | 57.54K | 157.06K | 151.50K | 130.14K | 4.15K | 7.28K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.05M | 194.70K | 138.91K | 102.52K | 94.73K | 87.62K | -395.10K | 8.67K | 3.80K | 4.80K | 3.99K | 2.63K | 0.00 | 0.00 | 0.00 |
| EBITDA | -13.72M | -1.85M | -5.15M | -2.51M | 660.55K | 96.65K | 288.98K | -984.03K | -133.27K | -2.00M | -2.08M | -148.09K | -28.50M | -28.19K | -8.73K |
| EBITDA Ratio | -74.89% | -22.18% | -52.11% | -9.80% | 8.88% | 6.36% | 24.92% | -39.65% | -19.70% | -95.35% | -217.60% | -18.37% | 0.00% | 0.00% | 0.00% |
| Operating Income | -7.26M | -2.76M | -5.29M | -1.78M | 565.82K | -87.62K | 395.10K | -984.03K | -987.05K | -1.43M | -2.08M | -150.71K | -28.50M | -28.19K | -8.73K |
| Operating Income Ratio | -87.80% | -24.08% | -53.51% | -10.40% | 7.61% | -2.29% | 13.48% | -39.65% | -19.77% | -95.67% | -218.02% | -18.70% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -6.46M | -362.72K | -23.59K | -29.39K | -778.17K | 96.65K | -106.11K | -165.83K | -119.51K | -580.57K | -7.28K | 0.00 | 28.47M | 0.00 | 0.00 |
| Income Before Tax | -13.72M | -3.91M | -5.32M | -2.54M | -284.43K | 9.04K | 288.98K | -1.17M | -1.12M | -2.01M | -2.09M | -150.71K | -28.50K | 0.00 | 0.00 |
| Income Before Tax Ratio | -165.86% | -34.15% | -53.75% | -14.81% | -3.82% | 0.24% | 9.86% | -47.27% | -22.38% | -134.47% | -218.78% | -18.70% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 5.34M | 400.34K | -1.20M | 29.39K | 125.30K | -154.20K | -50.94K | 1.62M | 130.14K | 576.42K | 7.28K | 0.00 | 28.50M | 28.19K | 8.73K |
| Net Income | -17.84M | -4.31M | -4.11M | -2.57M | -409.73K | 9.04K | 288.98K | -2.76M | -1.12M | -2.01M | -2.09M | -150.71K | -28.50M | -28.19K | -8.73K |
| Net Income Ratio | -215.70% | -37.65% | -41.59% | -14.98% | -5.51% | 0.24% | 9.86% | -111.21% | -22.38% | -134.47% | -218.78% | -18.70% | 0.00% | 0.00% | 0.00% |
| EPS | -23.35 | -7.63 | -7.58 | -4.99 | -1.04 | 0.02 | 0.81 | -7.89 | -3.20 | -6.30 | -13.50 | -0.97 | -273.59 | -0.27 | -0.11 |
| EPS Diluted | -7.49 | -7.63 | -7.58 | -4.99 | -1.04 | 0.02 | 0.81 | -7.87 | -3.20 | -6.07 | -13.35 | -0.97 | -269.45 | -0.27 | -0.11 |
| Weighted Avg Shares Out | 764.06K | 564.86K | 542.45K | 513.71K | 395.27K | 388.43K | 355.06K | 349.64K | 349.64K | 319.37K | 154.91K | 154.91K | 104.16K | 105.76K | 81.20K |
| Weighted Avg Shares Out (Dil) | 2.38M | 564.86K | 542.45K | 513.71K | 395.27K | 388.43K | 378.74K | 350.50K | 349.64K | 331.46K | 156.69K | 154.91K | 105.76K | 105.76K | 81.20K |
TRxADE HEALTH, INC. to Report Q4 and Year-End 2022 Financial Results on Monday, March 27th at 5:30 p.m.
TAMPA, FL / ACCESSWIRE / March 13, 2023 / TRxADE HEALTH INC. (NASDAQ:MEDS) , is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S.,...
All You Need to Know About TRxADE (MEDS) Rating Upgrade to Strong Buy
TRxADE (MEDS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
All You Need to Know About TRxADE (MEDS) Rating Upgrade to Buy
TRxADE (MEDS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
7 Meme Stocks Smart Investors Shouldn't Touch With a 10-Foot Pole
Meme stocks represented one of the most remarkable developments in the equities space during much of the new normal. However, by 2022, this sector received a very rude awakening.
TRxADE Health, Inc. (MEDS) Q3 2022 Earnings Call Transcript
TRxADE Health, Inc. (NASDAQ:MEDS ) Q3 2022 Earnings Conference Call November 7, 2022 5:00 PM ET Company Participants Janet Huffman - CFO & Principal Accounting Officer Surendra Ajjarapu - Founder, Chairman, CEO, Treasurer & Secretary Conference Call Participants Allen Klee...
TRxADE (MEDS) Reports Q3 Loss, Lags Revenue Estimates
TRxADE (MEDS) delivered earnings and revenue surprises of 50% and 27.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
TRxADE HEALTH, INC. to Report Third Quarter 2022 Financial Results on Monday, November 7th at 5:00 p.m.
TAMPA, FL / ACCESSWIRE / October 24, 2022 / TRxADE HEALTH INC. (NASDAQ:MEDS) , is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S.,...
3 High Volume Penny Stocks To Watch Before FOMC Meeting
High volume penny stocks for your September watch list. The post 3 High Volume Penny Stocks To Watch Before FOMC Meeting appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
TRxADE HEALTH, Inc.'s (MEDS) CEO Suren Ajjarapu on Q2 2022 Results - Earnings Call Transcript
TRxADE HEALTH, Inc. (NASDAQ:MEDS ) Q2 2022 Earnings Conference Call July 25, 2022 5:00 PM ET Company Participants Suren Ajjarapu - Founder, Chairman and CEO Janet Huffman - Chief Financial Officer Conference Call Participants Allen Klee - Maxim Group Howard...
TRxADE (MEDS) Reports Q2 Loss, Tops Revenue Estimates
TRxADE (MEDS) delivered earnings and revenue surprises of -44.44% and 13.07%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Source: https://incomestatements.info
Category: Stock Reports